PDCD1 and Familial prostate cancer: Although the U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an ICI targeting PD1, for individuals with TMB-High (defined as ≥10 mutations/Mb) solid tumors (41), evidence showed high TMB failed to predict response to ICIs across all cancer types including breast cancer, prostate cancer, and glioma (42).